JP2010518122A - 間質性肺疾患および喘息のためのトレプロスチニル処置 - Google Patents

間質性肺疾患および喘息のためのトレプロスチニル処置 Download PDF

Info

Publication number
JP2010518122A
JP2010518122A JP2009549268A JP2009549268A JP2010518122A JP 2010518122 A JP2010518122 A JP 2010518122A JP 2009549268 A JP2009549268 A JP 2009549268A JP 2009549268 A JP2009549268 A JP 2009549268A JP 2010518122 A JP2010518122 A JP 2010518122A
Authority
JP
Japan
Prior art keywords
treprostinil
pulmonary fibrosis
pharmaceutically acceptable
kit
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009549268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518122A5 (enExample
Inventor
ウェイド，マイケル
リッチ，スチュワート
サリバン，ユージン
ロシーニョ，ロバート
ジェフス，ロジャー
Original Assignee
ユナイテッド セラピューティクス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレーション filed Critical ユナイテッド セラピューティクス コーポレーション
Publication of JP2010518122A publication Critical patent/JP2010518122A/ja
Publication of JP2010518122A5 publication Critical patent/JP2010518122A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
JP2009549268A 2007-02-09 2008-02-08 間質性肺疾患および喘息のためのトレプロスチニル処置 Withdrawn JP2010518122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90032007P 2007-02-09 2007-02-09
US94021807P 2007-05-25 2007-05-25
PCT/US2008/053467 WO2008098196A1 (en) 2007-02-09 2008-02-08 Treprostinil treatment for interstitial lung disease and asthma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013116923A Division JP2013189459A (ja) 2007-02-09 2013-06-03 間質性肺疾患および喘息のためのトレプロスチニル処置

Publications (2)

Publication Number Publication Date
JP2010518122A true JP2010518122A (ja) 2010-05-27
JP2010518122A5 JP2010518122A5 (enExample) 2011-03-10

Family

ID=39357950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549268A Withdrawn JP2010518122A (ja) 2007-02-09 2008-02-08 間質性肺疾患および喘息のためのトレプロスチニル処置
JP2013116923A Pending JP2013189459A (ja) 2007-02-09 2013-06-03 間質性肺疾患および喘息のためのトレプロスチニル処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013116923A Pending JP2013189459A (ja) 2007-02-09 2013-06-03 間質性肺疾患および喘息のためのトレプロスチニル処置

Country Status (7)

Country Link
US (4) US20080280986A1 (enExample)
EP (2) EP2120961A1 (enExample)
JP (2) JP2010518122A (enExample)
KR (1) KR20090117781A (enExample)
CN (2) CN101678033A (enExample)
CA (1) CA2678258A1 (enExample)
WO (1) WO2008098196A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505082A (ja) * 2011-02-07 2014-02-27 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の処置のための新規組成物
KR20140070545A (ko) * 2011-08-12 2014-06-10 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
JP2014522878A (ja) * 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
JP2023523557A (ja) * 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
CN101287457B (zh) * 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
US20070023047A1 (en) * 2005-07-26 2007-02-01 Moshe Zalsman Face mask particularly useful as medical face mask
EP1962805B1 (en) 2005-12-08 2016-07-06 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
JP5797376B2 (ja) 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
EP3287434A1 (en) 2007-12-17 2018-02-28 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin ®
CA2723540C (en) * 2008-05-08 2016-01-05 United Therapeutics Corporation Treprostinil monohydrate
KR101544246B1 (ko) * 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
ES2451790T3 (es) * 2009-08-07 2014-03-28 Scipharm Sàrl Composición para el tratamiento de la fibrosis quística
JP5681276B2 (ja) 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
CA3029711A1 (en) 2010-06-03 2011-12-08 United Therapeutics Corporation Treprostinil production
US20120010159A1 (en) * 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
WO2012118943A1 (en) 2011-03-02 2012-09-07 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US20150272874A1 (en) * 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP4137127A1 (en) 2013-01-11 2023-02-22 Corsair Pharma, Inc. Prodrugs of treprostinil
CA3212313A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
WO2014150203A1 (en) 2013-03-15 2014-09-25 United Therapeutics Corporation Salts of treprostinil
CA2908244C (en) 2013-03-25 2021-04-20 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
KR102296259B1 (ko) 2013-10-25 2021-08-30 인스메드 인코포레이티드 프로스타사이클린 화합물, 조성물 및 이의 사용 방법
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
US20170088897A1 (en) * 2014-06-03 2017-03-30 Novartis Ag Pulmonary hypertension biomarker
WO2015192030A1 (en) 2014-06-13 2015-12-17 United Therapeutics Corporation Treprostinil formulations
CA2964804C (en) 2014-10-20 2019-04-02 United Therapeutics Corporation Synthesis of intermediate for producing prostacyclin derivatives
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US10632129B2 (en) 2014-12-03 2020-04-28 Steadymed Ltd. Preservative-free treprostinil formulations and methods and devices for use with same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
CN108379557A (zh) * 2018-01-15 2018-08-10 吉林大学 使用白介素因子-37治疗特发性肺纤维化
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
ES2976468T3 (es) 2018-09-18 2024-08-01 Lilly Co Eli Sal de treprostinil erbumina
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
EP4017588A1 (en) 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
CN116113415A (zh) 2020-06-09 2023-05-12 联合治疗公司 曲前列尼尔的富马酰基二酮哌啶前药
AU2021401921A1 (en) 2020-12-14 2023-07-06 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005225877A (ja) * 1997-11-14 2005-08-25 United Therapeutics Corp 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニレン）−１３，１４−ジヒドロ−プロスタグランジンＦ１の使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
PT90888B (pt) * 1988-06-17 1994-12-30 Wellcome Found Processo para a preparacao de composicoes farmaceuticas contendo prostaglandinas
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US6441245B1 (en) * 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
WO2000055314A2 (en) * 1999-03-18 2000-09-21 United Therapeutics Corporation Inhibitors of endothelin-1 synthesis
US6756047B2 (en) * 2000-05-12 2004-06-29 The University Of Toledo Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
JP5797376B2 (ja) * 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005225877A (ja) * 1997-11-14 2005-08-25 United Therapeutics Corp 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニレン）−１３，１４−ジヒドロ−プロスタグランジンＦ１の使用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505082A (ja) * 2011-02-07 2014-02-27 サイファーム ソシエテ ア レスポンサビリテ リミテ 嚢胞性線維症の処置のための新規組成物
US9504663B2 (en) 2011-02-07 2016-11-29 Scipharm Sarl Composition for the treatment of cystic fibrosis
KR20140070545A (ko) * 2011-08-12 2014-06-10 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
JP2014522878A (ja) * 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
JP2014527050A (ja) * 2011-08-12 2014-10-09 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
KR101997939B1 (ko) * 2011-08-12 2019-07-08 아센디스 파마 에이에스 담체-연결된 트레프로스티닐 전구약물
JP2023523557A (ja) * 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル

Also Published As

Publication number Publication date
EP2491932A2 (en) 2012-08-29
CN101678033A (zh) 2010-03-24
WO2008098196A1 (en) 2008-08-14
US20080280986A1 (en) 2008-11-13
EP2120961A1 (en) 2009-11-25
KR20090117781A (ko) 2009-11-12
CN102648916A (zh) 2012-08-29
EP2491932A3 (en) 2012-12-12
US20130096200A1 (en) 2013-04-18
US20120129941A1 (en) 2012-05-24
US20140018431A1 (en) 2014-01-16
CA2678258A1 (en) 2008-08-14
JP2013189459A (ja) 2013-09-26

Similar Documents

Publication Publication Date Title
JP2010518122A (ja) 間質性肺疾患および喘息のためのトレプロスチニル処置
ES2331187T3 (es) Utilizacion de treprostinil para mejorar las funciones renales.
JP6761929B2 (ja) Ｆｇｆ１９の新規な治療用途
JP5795165B2 (ja) 慢性虚血における亜硝酸塩の使用
US20190160150A1 (en) Acth for treatment of acute respiratory distress syndrome
JPH05505189A (ja) ３―グアニジノプロピオン酸の代謝障害の治療用組成物
CN107835695B (zh) 用于治疗自闭症的组合物和方法
US20250236676A1 (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
Chon et al. Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome
JP2016106121A (ja) Ｔｈ３マーチ関連疾患の治療及び予防用医薬組成物
EP4233851A1 (en) A soluble guanylat cyclase activator for treating chronic vascular dysfunction
JP2019514934A (ja) 全身性硬化症のためのイフェトロバン治療
Komori et al. Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis
CA2889826C (en) METHODS OF TREATING PULMONARY HYPERTENSION BY ADMINISTRATION OF A C-SIGNALLY NATRURETIC PEPTIDE RECEPTOR OF SEQUENCE ACTIVATORS
JP2025502098A (ja) うつ病の治療のための組成物及び方法
US20250387391A1 (en) A soluble guanylat cyclase activator for treating chronic vascular dysfunction
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
US20240408112A1 (en) Method for preventing or treating pulmonary arterial hypertension by using 7-dehydrocholesterols or salts, oxides, metabolites, or derivatives thereof
WO2025037259A1 (en) Methods and compositions for preventing or treating severe asthma
TW202532439A (zh) 治療氣喘之方法
WO2023218048A1 (en) Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis
Karsentya et al. SESSION PL ENIERE: METABOLISMES, DU GENE AU PATIENT
JP2000262495A (ja) 哺乳動物の寿命の判定方法および哺乳動物の抵抗性の判定方法
EP4221834A1 (en) Oxytocin treatment for hypermobile ehlers-danlos syndrome
WO2020036833A1 (en) Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131030

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131112

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141015

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150202